Free List Of Top 10 Monogenic Disease Gene Therapy Companies

Overview of Top 10 Monogenic Disease Gene Therapy Companies in the US

1. Company: Bluebird Bio

– Sector: Biotechnology

– Year Founded: 1992

– Annual Revenue: Approximately $50 million

– Description: Bluebird Bio focuses on developing gene therapies for severe genetic diseases and cancer. They are committed to transforming the lives of patients through innovative treatment approaches.

– Website: [Bluebird Bio](https://www.bluebirdbio.com/)

2. Company: Spark Therapeutics

– Sector: Biotechnology

– Year Founded: 2013

– Annual Revenue: Approximately $64 million

– Description: Spark Therapeutics is dedicated to challenging the inevitability of genetic diseases. They aim to deliver life-altering gene therapies for patients and families suffering from genetic disorders.

– Website: [Spark Therapeutics](https://sparktx.com/)

3. Company: Intellia Therapeutics

– Sector: Biotechnology

– Year Founded: 2014

– Annual Revenue: Approximately $30 million

– Description: Intellia Therapeutics is a leading genome editing company, working towards the development of curative treatments that can positively impact the lives of patients with severe and life-threatening diseases.

– Website: [Intellia Therapeutics](https://www.intelliatx.com/)

4. Company: Solid Biosciences

– Sector: Biotechnology

– Year Founded: 2013

– Annual Revenue: Approximately $20 million

– Description: Solid Biosciences is focused on developing meaningful therapies for Duchenne muscular dystrophy and other monogenic diseases. Their efforts are aimed at addressing the unmet needs of patients.

– Website: [Solid Biosciences](https://www.solidbio.com/)

5. Company: Editas Medicine

– Sector: Biotechnology

– Year Founded: 2013

– Annual Revenue: Approximately $47 million

– Description: Editas Medicine is a genome editing company that aims to translate the power and potential of CRISPR technology into transformative medicines for patients suffering from serious diseases.

– Website: [Editas Medicine](https://www.editasmedicine.com/)

6. Company: Sangamo Therapeutics

– Sector: Biotechnology

– Year Founded: 1995

– Annual Revenue: Approximately $83 million

– Description: Sangamo Therapeutics is committed to translating ground-breaking science into genomic therapies that transform patients’ lives. They focus on developing genomic medicines for genetic diseases.

– Website: [Sangamo Therapeutics](https://www.sangamo.com/)

7. Company: Crispr Therapeutics

– Sector: Biotechnology

– Year Founded: 2014

– Annual Revenue: Approximately $80 million

– Description: Crispr Therapeutics is at the forefront of the development of transformative gene-based medicines. Their goal is to create a new class of medicinal products for patients.

– Website: [Crispr Therapeutics](https://www.crisprtx.com/)

8. Company: Audentes Therapeutics

– Sector: Biotechnology

– Year Founded: 2012

– Annual Revenue: Approximately $48 million

– Description: Audentes Therapeutics is focused on developing and commercializing innovative gene therapy products for patients living with rare, life-threatening diseases.

– Website: [Audentes Therapeutics](https://www.audentestx.com/)

9. Company: Astellas Gene Therapies

– Sector: Biotechnology

– Year Founded: 2019

– Annual Revenue: Approximately $15 million

– Description: Astellas Gene Therapies is dedicated to advancing genetic medicines to address the unmet needs of patients with rare genetic diseases. Their innovative approach aims to make a meaningful impact on patients’ lives.

– Website: [Astellas Gene Therapies](https://astellasgenetherapies.com/)

10. Company: Voyager Therapeutics

– Sector: Biotechnology

– Year Founded: 2014

– Annual Revenue: Approximately $25 million

– Description: Voyager Therapeutics is focused on the development of life-changing gene therapies for severe neurological diseases. They are dedicated to transforming the lives of patients through innovative treatments.

– Website: [Voyager Therapeutics](https://www.voyagertherapeutics.com/)

The gene therapy landscape in the United States is witnessing remarkable advancements, with these top 10 companies leading the charge in developing innovative treatments for monogenic diseases. Their commitment to transforming the lives of patients through groundbreaking therapies reflects the immense potential of gene therapy in addressing genetic disorders.